Pharma's Big Defeat: US Rebate Proposal Hits The End Of The Road
Executive Summary
White House will not move forward with a rebate proposal the drug industry supported as a way to lower patient drug spending.
You may also be interested in...
Novo Nordisk Lowers Some Insulin List Prices, Following Lilly’s Lead
The company will lower the US list price of Levemir, NovoLog and certain other branded insulins by 65-75% and will also lower some unbranded insulin prices effective January 2024. Tresiba is not included.
Pharma On Its Back Foot As US Drug Price Reform Advances
Big pharma leaders warn of steep cuts to R&D and US jobs if US drug pricing reform legislation paves the way for direct government price negotiations.
Pharma On Its Back Foot As US Drug Price Reform Advances
Big pharma leaders warn of steep cuts to R&D and US jobs if US drug pricing reform legislation paves the way for direct government price negotiations.